

Stuart S Winter

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8896556/publications.pdf>

Version: 2024-02-01

34
papers

2,890
citations

623734

14
h-index

610901

24
g-index

34
all docs

34
docs citations

34
times ranked

4966
citing authors

#	ARTICLE	IF	CITATIONS
1	The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. <i>Nature</i> , 2012, 481, 157-163.	27.8	1,430
2	The genomic landscape of pediatric and young adult T-lineage acute lymphoblastic leukemia. <i>Nature Genetics</i> , 2017, 49, 1211-1218.	21.4	693
3	Improved Survival for Children and Young Adults With T-Lineage Acute Lymphoblastic Leukemia: Results From the Children's Oncology Group AALL0434 Methotrexate Randomization. <i>Journal of Clinical Oncology</i> , 2018, 36, 2926-2934.	1.6	164
4	Children's Oncology Group AALL0434: A Phase III Randomized Clinical Trial Testing Nelarabine in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia. <i>Journal of Clinical Oncology</i> , 2020, 38, 3282-3293.	1.6	136
5	Benign Hematogone-Rich Lymphoid Proliferations Can Be Distinguished From B-Lineage Acute Lymphoblastic Leukemia by Integration of Morphology, Immunophenotype, Adhesion Molecule Expression, and Architectural Features. <i>American Journal of Clinical Pathology</i> , 2000, 114, 66-75.	0.7	97
6	Safe integration of nelarabine into intensive chemotherapy in newly diagnosed T-cell acute lymphoblastic leukemia: Children's Oncology Group Study AALL0434. <i>Pediatric Blood and Cancer</i> , 2015, 62, 1176-1183.	1.5	76
7	Children's Oncology Group Trial AALL1231: A Phase III Clinical Trial Testing Bortezomib in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia and Lymphoma. <i>Journal of Clinical Oncology</i> , 2022, 40, 2106-2118.	1.6	45
8	Successful Outcomes of Newly Diagnosed T Lymphoblastic Lymphoma: Results From Children's Oncology Group AALL0434. <i>Journal of Clinical Oncology</i> , 2020, 38, 3062-3070.	1.6	42
9	High-Throughput Screening for Daunorubicin-Mediated Drug Resistance Identifies Mometasone Furoate as a Novel ABCB1-Reversal Agent. <i>Journal of Biomolecular Screening</i> , 2008, 13, 185-193.	2.6	29
10	Integration of ruxolitinib into dose-intensified therapy targeted against a novel JAK2 F694L mutation in B-cell precursor acute lymphoblastic leukemia. <i>Pediatric Blood and Cancer</i> , 2017, 64, e26328.	1.5	29
11	The Presence of CD34 ⁺ Cell Clusters Predicts Impending Relapse in Children With Acute Lymphoblastic Leukemia Receiving Maintenance Chemotherapy. <i>American Journal of Clinical Pathology</i> , 1998, 110, 313-320.	0.7	28
12	Patients with Early T-Cell Precursor (ETP) Acute Lymphoblastic Leukemia (ALL) Have High Levels of Minimal Residual Disease (MRD) at the End of induction: A Children's Oncology Group (COG) Study. <i>Blood</i> , 2009, 114, 9-9.	1.4	24
13	RUNX2 regulates leukemic cell metabolism and chemotaxis in high-risk T cell acute lymphoblastic leukemia. <i>Journal of Clinical Investigation</i> , 2021, 131, .	8.2	20
14	Germline RUNX1 variation and predisposition to childhood acute lymphoblastic leukemia. <i>Journal of Clinical Investigation</i> , 2021, 131, .	8.2	20
15	Dynamic pre-BCR homodimers fine-tune autonomous survival signals in B cell precursor acute lymphoblastic leukemia. <i>Science Signaling</i> , 2016, 9, ra116.	3.6	15
16	Capizzi-Style Methotrexate with Pegasparagase (C-MTX) Is Superior to High-Dose Methotrexate (HDMTX) in T-Lineage Acute Lymphoblastic Leukemia (T-ALL): Results from Children's Oncology Group (COG) AALL0434. <i>Blood</i> , 2015, 126, 794-794.	1.4	12
17	Pediatric Acute Leukemia Therapies Informed by Molecular Analysis of High-Risk Disease. <i>Hematology American Society of Hematology Education Program</i> , 2011, 2011, 366-373.	2.5	9
18	Dysregulated transcriptional networks in KMT2A- and MLLT10-rearranged T-ALL. <i>Biomarker Research</i> , 2018, 6, 27.	6.8	9

#	ARTICLE	IF	CITATIONS
19	The Genomic Landscape of Childhood T-Lineage Acute Lymphoblastic Leukemia. <i>Blood</i> , 2015, 126, 691-691.	1.4	4
20	Mixed Lineage Leukemia Rearrangements (MLL-R) Are Determinants of High Risk Disease in Homeobox A (HOXA)-deregulated T-Lineage Acute Lymphoblastic Leukemia: A Children's Oncology Group Study. <i>Blood</i> , 2015, 126, 694-694.	1.4	2
21	Precursor T Cell Acute Lymphoblastic Leukemia (T-ALL) Blasts Lose Expression of Markers of Immaturity during Chemotherapy: Implications for the Detection of Minimal Residual Disease.. <i>Blood</i> , 2008, 112, 1521-1521.	1.4	2
22	Inactivation of the INK4A/ARF (CDKN2) locus Cooperates with HMGA1 in T-Cell Leukemogenesis.. <i>Blood</i> , 2009, 114, 3969-3969.	1.4	2
23	PRC2 Mutations Induce Resistance to Conventional Chemotherapy By Inhibiting Mitochondrial Apoptosis in T-Cell Acute Lymphoblastic Leukemia. <i>Blood</i> , 2016, 128, 604-604.	1.4	1
24	VpreB Surrogate Light Chain Expression in B-Lineage ALL: A Report from the Children's Oncology Group. <i>Blood Advances</i> , 2021, , .	5.2	1
25	The emergence of antihistamines as unexpected allies in our fight against acute myeloid leukaemia. <i>EBioMedicine</i> , 2019, 48, 7-8.	6.1	0
26	Reply to A. K. Agrawal et al. <i>Journal of Clinical Oncology</i> , 2021, 39, 695-696.	1.6	0
27	Identification of Genomic Classifiers That Distinguish Induction Failure in T-Lineage Acute Lymphoblastic Leukemia in COG Study 9404.. <i>Blood</i> , 2006, 108, 1826-1826.	1.4	0
28	LEF1 Is a Tumor Suppressor in T Cell Acute Lymphoblastic Leukemia. <i>Blood</i> , 2008, 112, 3802-3802.	1.4	0
29	Absence of T-Cell Receptor Gene Rearrangements Predicts Induction Failure in Pediatric T-Cell Acute Lymphoblastic Leukemia.. <i>Blood</i> , 2009, 114, 910-910.	1.4	0
30	New Insights into Deregulated Gene Expression Pathways in MLL- and AF10-Rearranged T-Lineage Acute Lymphoblastic Leukemia. <i>Blood</i> , 2016, 128, 2906-2906.	1.4	0
31	Novel Mutation in CD46 in a Child with Atypical Hemolytic Uremic Syndrome (HUS) Characterized By Profound Thrombocytopenia and Anemia. <i>Blood</i> , 2016, 128, 4884-4884.	1.4	0
32	Genome-Based Treatment Algorithm to Prevent Relapse in Children and Young Adults with Acute Lymphoblastic Leukemia: A Prospective Feasibility Study. <i>Blood</i> , 2016, 128, 1738-1738.	1.4	0
33	JAK/STAT Pathway Inhibition Reverts IL7-Induced Glucocorticoid Resistance in a Subset of Human T-Cell Acute Lymphoblastic Leukemia. <i>Blood</i> , 2016, 128, 3963-3963.	1.4	0
34	A natural history study of nitrous oxide versus propofol-assisted intrathecal therapy in the treatment of acute lymphoblastic leukemia. <i>Pediatric Blood and Cancer</i> , 2022, , e29598.	1.5	0